Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So what you're posting is your opinion, not proof.
How do you suggest someone prove they are delivering, except if the company announces it in a news release or SEC filing, which you would not believe it anyway. The customers taking delivery are unlikely to announce it in a press release.
Can you prove they are not delivering? Same dilemma.
Makes sense, since the registration of those shares was recently rescinded by the company per the filings.
Uplisting using a RS is usually effective if there are sales to support the new share structure. AMBS did a RS to uplist without any revenue, and the stock sank. GC should have learned from that mistake, and Covid revenues look to be realized prior to a RS. Could be a much different story this time.
Be careful... mentioning Gerald's sales incentive bonuses is likely to get you accused of having privy insider knowledge from these clowns who don't understand the info is in the recent proxy statement filed with the SEC. LMAO
I agree. Pretty lucrative and hope he meets them. Seems doable given the markets they are now invested in and we all know Covid-19 isn't going away anytime soon.
You might be a moron if you believe any of the following:
1. I might be Gerald, the CEO
2. I might be privy to knowledge not available to other investors
3. I have any communication with the CEO or anyone at Amarantus or Todos Medical, except via Investor Relations contact
4. I am anything other than a radiochemist by profession and an investor in AMBS and TODMF
Anyone qualify for moron status? I think we have a few candidates already. Anyone else? Can you top the ridiculous moronic claims already made by loser investors who are suffering from Gerald Derangement Syndrome?
And I thought there was only the one moron posting here. Thanks for clearing it up. Did you lose as much money as JPetro?
Anyone with a web browser can easily figure out where Todos Medical is located. I don't see how fake news factors in, except in the claims of investors who lost a their A$$ in a high risk gamble.
JPetro made the same claim but doesn't have the sack to report it to the SEC. Pointless to make the claim here and not follow through. Comes across as petty. I am not affiliated with AMBS or TODMF as anything other than a shareholder and message board poster. I only own 1 share of AMBS, purchased for 0.7 cents to poke fun at another poster who stated I had no business posting unless I was a shareholder.
I wouldn't invest in a company if the CEO shared non-public info with me. Very shady. Apparently JPetro had a cozy relationship with the CEO while invested in AMBS, even reported to have had a Come to Jesus talk and afterwards tried to encourage shareholders to invest more. Still carrying the torch that this CEO is a scammer. Probably irritates him to no end that a newby like me is up over 50% in just a few months, especially with the same CEO he blames for his losses.
I like the direction Todos is moving with the Covid venture. Lots of risk but lots of upside if successful. With a penny stock I only invest what I can afford to lose.
Who is asking? An individual shareholder? As CEO I wouldn't answer those kinds of questions but would report via the filings at the appropriate time. I understand the AMBS history but that doesn't mean this company's venture into COVID-19 isn't legit.
This is a penny stock and I have stated from the beginning my investment is speculative. I risked what I am prepared to lose, unlike some who post here and on the AMBS board who lost hundreds of thousands in AMBS and assume no personal responsibility for their decisions.
My $10K Todos investment is in the green and growing. The expansion into Covid-19 space appears to be coming together and other investors are taking notice.
My $10K Todos investment is in the green and growing. The expansion into Covid-19 space appears to be coming together and other investors are taking notice. Apparently some are taking notice of of the AMBS relationship with Todos as well.
Please don't criticize the "investment analyst" for posting 7-year old news. The analyst's track record investing $200K+ in a penny stock speaks for itself. This forum is all the analyst has left to warn others:
"The CEO is a liar. No one should have listened to me when I was recommending the stock after my Come to Jesus talk with the CEO."
Also, there's the GDS and man-crush the analyst has to deal with. Sad.
How many times are you going to post the same false claim? Already rebutted in a previous post. Pathetic.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155794306
Posting on AMBS right out of the gate? How about 7 months later, after having already taken a position in Aytu Bioscience, a competitor to Todos. I'll say it again, if this is the best your DD can muster, no wonder you lost so much money in a penny stock. And then to pass yourself off as an investment analyst on a shareholder call. What a joke. You really can't make this stuff up. LMAO
3 amigos who all invested hundreds of thousands in a penny stock and lost it? You can't make this stuff up. Sounds more like 3 dumbass amigos. Why don't I see posts from either of them crying about their losses? Maybe they take some personal responsibility in their bad choices and don't try to blame it all on the CEO.
In your role as investment analyst did you recommend they buy shares? Or was that only after the Come to Jesus talk with Gerald?
Gotta laugh at the continued infatuation with Gerald pics.
Whatever. Same lame post.
Is it true you once posed as an investment analyst on a shareholder call? What kind of investment analyst risks hundreds of thousands of $$$ in a penny stock with no sales or revenues?
Who did you get to take the photo after you placed the bag over your head?
I'm not stuck in anything of the sort. I invested a small amount in a speculative play with TODOS, as I've clearly stated in my posts My goal with TOMDF is longer than the couple of months I've been invested. Your focus on the short term performance is indicative of a swing trader. My TOMDF investment may not pan out, which is why I invested a relatively small amount, vs. a multiple six-figure gamble on AMBS made by someone who spends their days/nights posting about their losses on a message board and blaming the CEO.
For any objective person who reads this post, who do you think would appear to be the bigger fool, the investor who is down $5K on a $10K gamble, or the investor who is down $200K? Not much thought required on that one.
I don't know Gerald. I've never spoken or communicated with him. I'll speculate the bigger fool here certainly must know what his hole tastes like, especially with the whole Come to Jesus conversation and all. Talk about comical. I wish some old-time AMBS investor could post a transcript or point me to where it's posted... would surely make for a good laugh.
Someone must have had a Come to Jesus talk with GC and tried to convince other investors they should be buying shares. Rumor has it that kind of thing has happened before. Might explain the sudden interest today.
I'm holding out hope all these developments drive the share price higher. Like you, I'm still holding my AMBS shares (in my case, my share). Good to know there's still hope left and longtime shareholders continue to have enough confidence in the company and CEO to continue holding their shares.
Posting PRs from 7 years ago, but still holding his shares, after investing several hundred thousand $$$ in a high-risk penny stock. Places all blame on CEO and none on his own actions. Little chance of moving on. Sad, really.
Todos Medical Enters Into Cross-Distribution Agreement With L1 Systems for Ventilators and COVID Testing
Amarantus connection in RED
https://investor.todosmedical.com/news-events/press-releases/detail/54/todos-medical-enters-into-cross-distribution-agreement-with
MAY 26, 2020 9:19AM EDT
• Todos gains distribution rights to LifeCan Ventilator in Brazil, Mexico & Latin America
• Ventilator access will help prospective government and NGO procurers of COVID-related medical products reduce need for additional suppliers to address critical health needs
• L1 distribution network will provide untapped market access for Todos’ tests
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, May 26, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a cross-distribution agreement with L1 Systems, Ltd., a wholly-owned subsidiary of Medigus, Ltd. (NASDAQ:MDGS) (TASE:MDGS), for the distribution of COVID-19 related products, including ventilators. Todos is making available to L1 its comprehensive suite of testing solutions that covers best-in-class RNA extraction equipment, RNA extraction reagents, qPCR reagents, Digital PCR reagents and US-validated SARS-CoV-2 rapid point-of-care antibody test kits for non-exclusive distribution. L1 is making available to Todos the LifeCan ventilators, manufactured by Elbit Systems, for non-exclusive distribution in Mexico and Latin America, including Brazil. This agreement strengthens both companies’ core offerings and allows each company to focus on markets where they are developing reliable sales channels.
“Given that Todos’ team has been focused recently on penetrating the Latin American market, where a marked uptick in COVID-19 infections has led to a significantly increased need for COVID-19 testing and critical care treatment options, we believe gaining access to a high quality medical grade ventilator will further bring attention to Todos’ test offering due to the severe global shortage in ventilators,” said Gerald Commissiong, President & CEO of Todos Medical.
Mr. Commissiong continued, “When a country is dealing with a pandemic crisis such as COVID-19, getting trusted sources of medical supplies from which a procurement agent can acquire multiple lines of needed products substantially increases a supplier’s profile within that procurement agency, and provides the supplier an opportunity to expose the procurer to the rest of its portfolio in a more comprehensive way. Ventilators are often the difference between life and death when treating patients, and we believe getting access to a nimble and tailored product such as LifeCan – a simple, high-quality product that was designed in Israel to respond to many of the recent concerns with the established medical ventilator designs – gives Todos a significant edge when competing for contracts from foreign governments, hospital systems and others users of healthcare products and services. As we continue to build our international import/export division, this agreement positions Todos to stand out from other companies competing for contracts in key markets.”
About the SARS-CoV-2 Coronavirus (COVID-19)
Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses can be transmitted between animals and people and evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, Hubei Province of China, and additional cases have been found in a growing number of countries worldwide. COVID-19 is the disease caused by SARS-CoV-2.
About Medigus, Ltd.
Medigus is traded on the Nasdaq Capital Market and the TASE (Tel Aviv Stock Exchange). To learn more about the company’s advanced technology, please visit www.medigus.com.
About Todos Medical Ltd.
Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020.
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020.
Todos recently entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements with multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has formed Corona Diagnostics, LLC, a strategic collaboration with Emerald Organic Products, Inc. (OTC: EMOR), to support telemedicine and virtual pharmacy aspects of the commercialization of its COVID-19 return to work testing programs in the US.
For more information, please visit https://www.todosmedical.com/
Todos Medical Enters Into Cross-Distribution Agreement With L1 Systems for Ventilators and COVID Testing
MAY 26, 2020 9:19AM EDT
• Todos gains distribution rights to LifeCan Ventilator in Brazil, Mexico & Latin America
• Ventilator access will help prospective government and NGO procurers of COVID-related medical products reduce need for additional suppliers to address critical health needs
• L1 distribution network will provide untapped market access for Todos’ tests
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, May 26, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a cross-distribution agreement with L1 Systems, Ltd., a wholly-owned subsidiary of Medigus, Ltd. (NASDAQ:MDGS) (TASE:MDGS), for the distribution of COVID-19 related products, including ventilators. Todos is making available to L1 its comprehensive suite of testing solutions that covers best-in-class RNA extraction equipment, RNA extraction reagents, qPCR reagents, Digital PCR reagents and US-validated SARS-CoV-2 rapid point-of-care antibody test kits for non-exclusive distribution. L1 is making available to Todos the LifeCan ventilators, manufactured by Elbit Systems, for non-exclusive distribution in Mexico and Latin America, including Brazil. This agreement strengthens both companies’ core offerings and allows each company to focus on markets where they are developing reliable sales channels.
“Given that Todos’ team has been focused recently on penetrating the Latin American market, where a marked uptick in COVID-19 infections has led to a significantly increased need for COVID-19 testing and critical care treatment options, we believe gaining access to a high quality medical grade ventilator will further bring attention to Todos’ test offering due to the severe global shortage in ventilators,” said Gerald Commissiong, President & CEO of Todos Medical.
Mr. Commissiong continued, “When a country is dealing with a pandemic crisis such as COVID-19, getting trusted sources of medical supplies from which a procurement agent can acquire multiple lines of needed products substantially increases a supplier’s profile within that procurement agency, and provides the supplier an opportunity to expose the procurer to the rest of its portfolio in a more comprehensive way. Ventilators are often the difference between life and death when treating patients, and we believe getting access to a nimble and tailored product such as LifeCan – a simple, high-quality product that was designed in Israel to respond to many of the recent concerns with the established medical ventilator designs – gives Todos a significant edge when competing for contracts from foreign governments, hospital systems and others users of healthcare products and services. As we continue to build our international import/export division, this agreement positions Todos to stand out from other companies competing for contracts in key markets.”
About the SARS-CoV-2 Coronavirus (COVID-19)
Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses can be transmitted between animals and people and evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, Hubei Province of China, and additional cases have been found in a growing number of countries worldwide. COVID-19 is the disease caused by SARS-CoV-2.
About Medigus, Ltd.
Medigus is traded on the Nasdaq Capital Market and the TASE (Tel Aviv Stock Exchange). To learn more about the company’s advanced technology, please visit www.medigus.com.
About Todos Medical Ltd.
Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020.
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020.
Todos recently entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements with multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has formed Corona Diagnostics, LLC, a strategic collaboration with Emerald Organic Products, Inc. (OTC: EMOR), to support telemedicine and virtual pharmacy aspects of the commercialization of its COVID-19 return to work testing programs in the US.
For more information, please visit https://www.todosmedical.com/
https://investor.todosmedical.com/news-events/press-releases/detail/54/todos-medical-enters-into-cross-distribution-agreement-with
I'm making my prediction based on notes previously posted from the Swiss Growth Forum. GC talked a lot about Brazil, so there is clearly strong interest in addressing the testing demand there.
I expect to see Todos update this week or next on sales strategy for Brazil COVID-19 testing.
And then there's the delusional investor who bet hundreds of thousands of dollars on a penny stock and lost, and posts incessantly on a message board blaming the CEO for his loss. No pretending about that, it's all here for anyone who takes the time to read.
Here's something that may help next time.
That's original... Gerald's personal hygiene douche. You would know about that, based on your posts when you were pumping the stock. How much did you invest in this penny stock again? Several hundred thousand dollars is what I read from your posts. Insane. I can understand the anger with a loss of that magnitude. Gerald made you do it, correct?
Wrong again. Here's the actual timeline, easily determined from my profile if you had actually taken the time to investigate before posting your false claim.
8/18/19 - Alias created - 9 months ago (more than a few months)
8/18/19 - First post to IHUB message boards
3/19/20 - Sold AYTU, invested in Todos Medical - Same CEO as Amarantus
3/20/20 - First post to Amarantus and Todos Medical boards - 7 months after alias created
5/11/20 - Purchased 1 AMBS share to become legitimate shareholder to satisfy JCacciabeve's concerns - trade posted
Hardly straight to the AMBS rag as you claim. Did you do any due diligence when Gerald was feeding you his "lies"? If your DD was no better than this, it's no wonder you lost so much money in the investment.
I've been tracking AYTU Bioscience as well. The initial news of COVID-19 test kits drove the price up 700%, but since then it's been trading in a limited range since then.
I'm not accessing through a Twitter account. I'm using this link.
https://twitter.com/G_Commish/
The conference was yesterday. Give it time. Sounds like we will get some substantial updates in the coming weeks that may have more impact on the needle. I especially like the part about establishing revenue streams prior to any move to uplist.
Corrected link: Brazil Hits record high for new coronavirus cases
https://www.cnn.com/2020/05/20/americas/brazil-coronavirus-deaths-intl/index.html
Another post regarding Todos and Brazil, from another board.
Todos Medical presented at Swiss Growth Forum on May 21, 2020. These are notes posted by an investor on another Todos message board. IHUB probably won't allow a link to a competitors board, but the post content provides a quick review of the presentation for investors.
I'm not seeing that warning. I guess they got the problem corrected.
"I never stated or supported the claim... but if it were true..."
You should run for Congress. With that line of rationale, you would fit right in.
Do you continue to hold your AMBS shares? Are you, like another poster, hopeful that Todos Medical can have a positive impact on AMBS share price? Hard to figure out that line of reasoning when one believes the same CEO is a liar and scammer. But I suppose anyone who invests a large sum in a penny stock isn't thinking clearly to start with.
Another question... why did you invest hundreds of thousands of dollars in a penny stock? Oh, that's right, that was Gerald's fault as well. No part of that decision was your responsibility.
Your post supported the claim by JCacciabeve that I am posting here as GC. Both posts were deleted. Have them restored by the admin and I will show you. Does a moderator have the ability to do that?
Who do you think you're communicating with? I am not GC. What kind of idiotic thought process led to that conclusion?
If you believe I am, then you are clearly infected with Gerald Derangement Syndrome, as are a few others here who suggested the same. GDS for short. So incredibly sad that an investor not only lost money on a penny stock, but they continue posting for years on a message board thinking they are helping to steer other investors away, while still blaming the CEO for their loss. Get help. Seriously.
I'm not the poster who stated that posting here while owning no shares makes one a loser. The was JCacciabeve. I don't care if JP owns shares or not, but it's odd how he won't answer the question. Probably doesn't want to be a hypocrite. He was once one of the biggest pumpers of the stock, based on his posting history. How many people who he influenced with his great drill down into the stock now think JP is a liar?
The CEO made statements that didn't pan out. Is that because he knowingly made false statements, or because that's your perception when the plan didn't go as intended and the losses started to mount? Who is to blame for dumping hundreds of thousands of dollars into a penny stock? The CEO? I hardly think so.
If I go to Vegas and bet $200K on RED because the roulette table attendant tells me RED is a good bet and I can double my money quickly, then whose fault is it when the marble scores BLACK? Oh yeah, its the attendant's fault for lying to me. Typical reaction for today's culture. No personal responsibility at all for losing money on a high risk bet. As I understand it, the CEO and his father both invested personal assets. I guess GC was lying to himself and his Dad as well. Not trying to defend the guy. Maybe he was lying. Just pointing out the apparent lack of any personal responsibility of those posting here who lost money on a high risk bet.
GC's seems to be following through so far on his goals with Todos in the short time he's been CEO. Perhaps he learned from his past mistakes. He said they would parter with manufacturers to bring COVID-19 testing to market. He said they would complete testing in a CLIA lab to validate the manufacturers claimed results. Both those goals have been met. The first test sales were announced yesterday. I'm sorry, but my experience so far doesn't match yours.
Welcome back to the board in the new alias created just today. What was your alias when you were an investor? Would be interesting to look up the posting history.
That's an interesting article, and I thank you for sharing. I agree, it does present a potential roadblock to the level of sales Todos might achieve. However, as the article indicates, some areas have sufficient testing capability, while many others do not. The lack of participation in testing is described by several factors, which include lack of patient knowledge that testing is now available for them, as well as states that have not relaxed the restrictions on testing, even after testing supplies have ramped up to adequate levels. I expect testing demand will increase when people become more aware of the relaxed requirements and especially if the testing is provided for free or minimal cost to them. Insurers will include this in preventative care and federal funding will cover the rest.
I expect Todos testing sales to continue to grow... to what level is anyone's guess. I understand you believe it will be close to zilch. I expect it will be a lot higher. Time will tell as to who is correct.
Regarding your 2nd point, that isn't part of my hypothesis. I asked if you still owned AMBS shares. Yes or No. Why do you continue to avoid this question? If you sold out, good for you, but according to JC's definition you are a loser if you post here without owning shares. If you do continue to hold shares, then I ask for what purpose, especially since you believe the CEO is a con man and completely incompetent. Are you expecting your shares to rise in value based on any of the initiatives the CEO started? Just trying to understand where you're coming from, but so far all I get in response is avoidance and deflection. Answering a simple question of share ownership shouldn't be this hard.
I purchased $10K of Todos shares, which appears to be far less than the hundreds of thousands you invested in AMBS. I can understand why you are so bitter about your investment, but it has nothing to do with my investment. I won't invest more than this amount in a penny stock. Unfortunate that you did, but the CEO is not to blame for your decision. Penny stocks are highly speculative, and any investment advisor will recommend investing only what you're comfortable losing. I also understand that in today's culture no one accepts any personal responsibility for their decisions... only if they win, whereby they brag to their friends about their shrewd investment insight and all the money they made; If they lose, it's always someone else's fault.
I just checked my TDA account and it shows up there as well. Not sure what your issue is, but I'm seeing today's news in both TDA and Fidelity accounts.